Original Article Clinical Outcomes of Sirolimus with Eluting Stent Implantation in Coronary Artery Disease

Objective: To evaluate the immediate post procedure, thirty-days, and six-months clinical outcomes of sirolimus-eluting stents (SES) implantation in patients with single and multivessel coronary artery disease (CAD). Methods: A case series of all consecutive patients undergoing percutaneous coronary interventions (PCI) with SES implantation at Shifa International Hospital, Islamabad, were evaluated at early post-procedure, 30-days and six-months clinical follow-up for the incidence of major adverse cardiac event (MACE). This included death, nonfatal myocardial infarction (MI) and repeat revascularization. Results: Out of 206 consecutive patients, 324 had SES implanted. Cumulative MACE rate was 2.93 % and 6% at 30-days and six-months follow-ups respectively. Five patients developed ST-segment elevation MI (STEMI). One patient developed non-STEMI. Emergency Coronary Artery Bypass Grafting (CABG) was done in two patients. Repeat (PCI) was carried in three (1.46%) patients for acute in-stent thrombosis. Diabetes Mellitus and multivessel stenting were found to be the independent predictors for acute in-stent thrombosis (P-value <0.02 and 0.05 respectively). Conclusion: SES implantation in coronary artery disease can be safe and effective MACE at one and six months follow-ups (JPMA 58:449;2008)